Halozyme Therapeutics Aktie
45,42
EUR
+0,41
EUR
+0,91
%
47,85
USD
+0,55
USD
+1,16
%
Halozyme Therapeutics Aktie Analyse
15.11.24 | Halozyme Therapeutics Neutral | JP Morgan Chase & Co. | |
27.09.12 | Halozyme Therapeutics neutral | UBS AG | |
12.08.08 | Halozyme Therapeutics hold | Brean Murray, Carret & Co., LLC |